Cerebellar liponeurocytoma

Summary

Cerebellar liponeurocytoma (MONDO:0006131) is a disease and 1 clinical trial. Top therapeutic interventions include dabrafenib and trametinib. A subtype of cerebellar neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebellar liponeurocytoma
Mondo ID	MONDO:0006131
EFO	EFO:1000159
Orphanet	251931
DOID	DOID:6458
NCIT	C6905
SNOMED CT	716592003
UMLS	C1370507
MedGen	237160
GARD	0010642
Is cancer (heuristic)	no

Also known as: cerebellar liponeurocytoma · cerebellar liponeurocytoma (WHO grade II) · CLNC · lipomatous medulloblastoma · lipomatous medulloblastoma (formerly)

Disease family

This is a subtype of cerebellar neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › cerebellar neoplasm › cerebellar liponeurocytoma

Related subtypes (7): cerebellar astrocytoma, adult cerebellar neoplasm, papillary meningioma of the cerebellum, childhood cerebellar neoplasm, medulloblastoma, cancer of cerebellum, benign neoplasm of cerebellum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03975829	PHASE4	RECRUITING	Pediatric Long-Term Follow-up and Rollover Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DABRAFENIB	4	1
TRAMETINIB	4	1
CHEMBL5433950	0	1